CLINICAL & PIPELINE·Drug Approval
RISING Secures FDA Approval for Sevelamer Hydrochloride Generic, Marketing Status Discontinued
RISING secured FDA approval on December 15, 2020, for its Abbreviated New Drug Application (ANDA) for Sevelamer Hydrochloride 400mg and 800mg tablets. Despite this regulatory milestone, the marketing status for both approved products is listed as "Discontinued." This indicates RISING is not actively marketing these generic Sevelamer Hydrochloride formulations, impacting immediate market competition and procurement strategies for this phosphate binder.
90-Day Activity